Cellebrite DI (NASDAQ:CLBT) Stock Breaks Below 50 Day Moving Average - What's Next?

Key Points

• Cellebrite shares fell below their 50-day moving average, trading as low as $10.88 versus the average of $11.61.
• The company beat quarterly earnings and revenue expectations, but its fourth-quarter revenue outlook of $145 million–$150 million fell short of the $151.6 million consensus estimate.
• Analysts maintain a “Moderate Buy” consensus and an average $14.62 price target, though several firms recently cut their targets.

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $11.61 and traded as low as $10.88. Cellebrite DI shares last traded at $10.89, with a volume of 6,493,762 shares trading hands.

More Cellebrite DI News

Here's some of the latest news about CLBT:

• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million–$558 million includes the $556.8 million consensus estimate, suggesting the annual outlook was broadly on target. Cellebrite third-quarter results
• Neutral Sentiment: Chief Revenue Officer Marcus Jewell sold 393 shares, about 0.09% of his holdings, and retained 426,735 shares; the small sale is unlikely to be a major signal on its own. SEC insider transaction filing
• Negative Sentiment: Fourth-quarter revenue guidance of $145 million–$150 million was below the $151.6 million consensus estimate. The softer near-term outlook likely weighed on shares despite the quarterly revenue beat. Cellebrite third-quarter results

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. DA Davidson restated a "buy" rating and set a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. Lake Street Capital cut their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings downgraded Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, August 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $14.62.

Cellebrite DI Trading Down 14.3%

The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 1.95 and a beta of 1.06. The firm's 50-day moving average is $11.61 and its 200 day moving average is $13.24.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.08. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. The company had revenue of $149.02 million during the quarter, compared to analysts' expectations of $145.83 million. Analysts predict that Cellebrite DI Ltd. will post 0.37 EPS for the current year.

Insider Transactions at Cellebrite DI

In other news, CFO David Barter sold 12,134 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total value of $136,022.14. Following the completion of the sale, the chief financial officer directly owned 322,085 shares of the company's stock, valued at $3,610,572.85. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CRO Marcus Jewell sold 12,562 shares of the firm's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the transaction, the executive directly owned 427,128 shares in the company, valued at $4,800,918.72. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 56,909 shares of company stock worth $641,890. Insiders own 5.70% of the company's stock.

Institutional Trading of Cellebrite DI

A number of large investors have recently bought and sold shares of CLBT. Light Street Capital Management LLC lifted its holdings in shares of Cellebrite DI by 104.8% in the second quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company's stock worth $19,166,000 after buying an additional 671,830 shares in the last quarter. Roubaix Capital LLC lifted its holdings in shares of Cellebrite DI by 108.1% during the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company's stock worth $4,178,000 after acquiring an additional 157,536 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Cellebrite DI in the 1st quarter worth about $2,134,000. Nine Ten Capital Management LLC boosted its stake in Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock worth $60,251,000 after buying an additional 682,933 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Cellebrite DI by 33.9% in the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company's stock valued at $29,712,000 after purchasing an additional 545,334 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.